Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. - Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC (Expert review of pharmacoeconomics & outcomes research, 2024)